(S)-(+)-Ibuprofen - CAS:51146-56-6

您当前的位置：

(S)-(+)-Ibuprofen (Synonyms:(S-(+)-布洛芬; (S)-Ibuprofen))

目录号 : KM17891 CAS No. : 51146-56-6 纯度 : 98%

Data Sheet 产品使用指南

(S)-(+)-Ibuprofen ((S)-Ibuprofen)，一种 Ibuprofen 的 S(+)-对映异构体，是一种有效的 COX-1 和 COX-2 抑制剂，IC₅₀ 分别为 2.1μM 和 1.6 μM。(S)-(+)-Ibuprofen 具有止痛，抗炎，抗癌和退热作用。

规格	价格	是否有货
500mg		In-stock
1g		In-stock
5g		In-stock
10g	询价	In-stock
50g	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Kgp-IN-1 hydrochloride In-stock
Ginkgolide A In-stock
Ginkgetin In-stock
VKGILS-NH2 In-stock
7,3',4'-Tri-O-methylluteolin In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC₅₀s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.

体外研究

(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent.
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis.
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 µM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1.
(S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation.
(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC₅₀ of 61.7 μM.

Cell Proliferation Assay

Cell Line:	HCT-15 and HCA-7 cells
Concentration:	0 µM, 200 µM, 400 µM, 600 µM, 700 µM, 800 µM, 900 µM, and 1000 µM
Incubation Time:	8 days
Result:	Reduced concentration dependently cell survival in both cell lines to a similar extent.

Cell Cycle Analysis

Cell Line:	HCT-15 and HCA-7 cells
Concentration:	0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM, and 1000 µM
Incubation Time:	24 hours (HCT-15) or 20 hours (HCA-7)
Result:	Caused a G0/G1 phase block.

Apoptosis Analysis

Cell Line:	HCT-15 and HCA-7 cells
Concentration:	0 µM, 200 µM, 400 µM, 600 µM, 800 µM, 900 µM, and 1000 µM
Incubation Time:	72 hours
Result:	Induced cell apoptosis.

Western Blot Analysis

Cell Line:	HCT-15 and HCA-7 cells
Concentration:	900 µM
Incubation Time:	4 hours, 8 hours, 16 hours, 24 hours, 32 hours, 48 hours and 72 hours
Result:	Decreased levels of Cyclin D1 protein.

体内研究

(S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model.

Animal Model:	NMRI (nu/nu) male mice (6-8 week old ) injected with HCA-7 and HCT-15 cells
Dosage:	15 mg/kg/day
Administration:	Intraperitoneal injection; five days a week; for 4 weeks
Result:	Inhibited tumor growth of HCA-7 and HCT-15 xenografts in mice.

分子式

C₁₃H₁₈O₂

分子量

206.28

CAS号

51146-56-6

中文名称

(S)-(+)-布洛芬

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 100 mg/mL (484.78 mM; Need ultrasonic)

Ethanol : 100 mg/mL (484.78 mM; Need ultrasonic)

H₂O : 1 mg/mL (4.85 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.8478 mL	24.2389 mL	48.4778 mL
5 mM	0.9696 mL	4.8478 mL	9.6956 mL
10 mM	0.4848 mL	2.4239 mL	4.8478 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.12 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.12 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.12 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
4.

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.12 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
5.

请依序添加每种溶剂： 10% EtOH 90% corn oil
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (12.12 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中，混合均匀。